PubMed

Clin Cosmet Investig Dermatol. 2026 Oct 29;19:642546. doi: 10.2147/CCID.S642546. eCollection 2026. ABSTRACT INTRODUCTION: Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation and compromised epidermal barrier function. Although tight junction disruption is a key pathological hallmark, the upstream transcriptional mechanisms driving the downregulation of core barrier proteins such as claudin-1 (CLDN1) remain insufficiently characterized. METHODS: We im

Clin Cosmet Investig Dermatol. 2026 Oct 29;19:620524. doi: 10.2147/CCID.S620524. eCollection 2026. ABSTRACT BACKGROUND: Psoriasis and acute myocardial infarction (AMI) are both closely associated with immune-inflammatory dysregulation; however, the shared molecular features of psoriasis-AMI comorbidity remain incompletely characterized. To address this gap, this study aimed to identify novel shared inflammation-related candidate genes between psoriasis and AMI and to characterize their cellular

J Nutr Metab. 2026 Nov 1;2026:7365660. doi: 10.1155/jnme/7365660. eCollection 2026. ABSTRACT Psoriasis is a chronic inflammatory skin disorder characterized by dysregulated immune responses and excessive keratinocyte proliferation, with substantial effects on patients' quality of life. Evidence suggests that the gut microbiota and the gut-skin-immune axis may contribute to systemic inflammation and immune dysregulation associated with psoriasis. This narrative review examines the potential immun

Biomark Med. 2026 Nov 3:1-16. doi: 10.1080/17520363.2026.2756984. Online ahead of print. ABSTRACT AIM: This systematic review and meta-analysis aimed to quantitatively evaluate calcitonin gene-related peptide (CGRP) concentrations across autoimmune diseases (psoriasis, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis) and assess its clinical utility as a neuro-immune biofluid biomarker. MATERIALS AND METHODS: PRISMA-compliant meta-analyses using random-effects models calculat

Ann Med. 2026 Dec;58(1):2749195. doi: 10.1080/07853890.2026.2749195. Epub 2026 Nov 2. ABSTRACT BACKGROUND: Hyperkeratotic palmoplantar lesions (HPPLs), primarily encompassing palmoplantar psoriasis (PPP) and hyperkeratotic palmoplantar eczema (HPKE), present a significant diagnostic challenge due to overlapping clinical morphological features. This study evaluates the diagnostic accuracy of dermoscopy as a non-invasive bridge between clinical evaluation and standard histopathology. METHODS: An o

J Dermatol Sci. 2026 Oct 14:S0923-1811(26)00174-X. doi: 10.1016/j.jdermsci.2026.10.002. Online ahead of print. NO ABSTRACT PMID:42971898 | DOI:10.1016/j.jdermsci.2026.10.002 View the full article

J Am Acad Dermatol. 2026 Nov 2:S0190-9622(26)03840-5. doi: 10.1016/j.jaad.2026.10.085. Online ahead of print. ABSTRACT BACKGROUND: The NPF/IPC statement exempts routine tuberculosis (TB) testing for IL-17/IL-23 inhibitors in low-burden settings, but elimination may be unsafe in high-burden regions. OBJECTIVE: To develop and evaluate a clinical score estimating the probability of a high pretreatment interferon-γ release assay (IGRA) response in psoriasis patients before biologic therapy in China.

Int Immunopharmacol. 2026 Nov 2;191(Pt 1):117608. doi: 10.1016/j.intimp.2026.117608. Online ahead of print. ABSTRACT BACKGROUND: Generalized pustular psoriasis (GPP) is a severe autoinflammatory dermatosis driven by excessive IL-1/IL-36-neutrophil activation, with high disease burden and limited therapeutic options. The mechanisms underlying dysregulated neutrophil recruitment remain incompletely understood, and the lack of mechanistic models that capture key inflammatory features of GPP has lim

Dermatologie (Heidelb). 2026 Nov 2. doi: 10.1007/s00105-026-05804-0. Online ahead of print. ABSTRACT A 60-year-old chemistry lab technician underwent a tertiary individual prevention program due to hand eczema that was believed to be work-related and refractory to treatment. While the clinical signs on her hand were inconclusive, discrete psoriasiform skin lesions were observed on the glutes. Molecular classification confirmed the diagnosis. After switching to calcipotriol and acitretin, the con

Acta Derm Venereol. 2026 Nov 2;106:0624. doi: 10.2340/actadv.v106.adv-2026-0624. NO ABSTRACT PMID:42969559 | PMC:PMC13725811 | DOI:10.2340/actadv.v106.adv-2026-0624 View the full article

Arch Rheumatol. 2026 Sep 9. doi: 10.5152/ArchRheumatol.2026.25145. Online ahead of print. ABSTRACT BACKGROUND/AIMS: This study aimed to assess the utility of the neutrophil‑to‑lymphocyte ratio (NLR), C‑reactive protein (CRP), and skin lesion severity for identifying arthritic manifestations in individuals with psoriasis. MATERIALS AND METHODS: A total of 102 patients with psoriasis vulgaris (PsV), 74 with psoriatic arthritis (PsA), and 60 healthy controls were enrolled. Demographic and laborator

eGastroenterology. 2026 Oct 30;4(4):e100708. doi: 10.1136/egastro-2026-100708. eCollection 2026. ABSTRACT Interleukin (IL)-23 inhibition is now an established therapeutic strategy in inflammatory bowel disease (IBD), supported by the efficacy of selective IL-23p19 monoclonal antibodies in both Crohn's disease (CD) and ulcerative colitis (UC). Advances in peptide engineering have also enabled direct oral targeting of the IL-23 receptor (IL-23R), introducing an alternative approach to inhibition o

J Biomed Mater Res A. 2026 Nov;114(11):e70182. doi: 10.1002/jbm.a.70182. ABSTRACT Enzyme therapeutics are often limited by poor stability, rapid clearance, and systemic effects that reduce therapeutic efficacy and necessitate high dosing. Enzyme-biomaterial conjugation can address these limitations and improve outcomes by localizing therapeutics at the tissue site of intended action. In particular, indoleamine 2,3-dioxygenase (IDO), a potent immunomodulatory enzyme, has demonstrated therapeutic

J Dermatol. 2026 Nov 1. doi: 10.1111/1346-8138.70560. Online ahead of print. ABSTRACT Vunakizumab is a humanized anti-IL-17A monoclonal antibody approved in China for moderate-to-severe plaque psoriasis. Real-world data on its effectiveness and predictors of response remain scarce. This prospective, single-center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks). PASI, PGA, BSA, and DLQI were assessed at baseline and we

Eur J Pharm Biopharm. 2026 Nov 1:115284. doi: 10.1016/j.ejpb.2026.115284. Online ahead of print. ABSTRACT Overcoming the thickened stratum corneum is critical for effective topical psoriasis therapy. To address this, we engineered chemically cross-linked sodium alginate/poly(vinyl alcohol) hydrogels enriched with Aloe vera. These incorporate thermosensitive carriers co-loaded with salicylic acid and fluocinolone acetonide, enabling sustained drug release and enhanced penetration. Crucially, eval